Literature DB >> 7954140

Net economic costs of dementia in Canada.

T Ostbye1, E Crosse.   

Abstract

OBJECTIVE: To estimate the net economic costs of dementia in Canada in 1991 by comparing costs related to elderly patients with dementia with those related to elderly people without dementia.
DESIGN: Cost-of-illness study. DATA SOURCES: Most of the data analysed in this study were from the Canadian Study of Health and Aging (CSHA), in which 10,263 Canadians aged 65 years and over were randomly selected, surveyed and, when appropriate, given clinical examinations. Data on patients with dementia and on people without cognitive impairment (control subjects) were used for this analysis. Data on activities of daily living (ADLs) were taken from a separate study under the CSHA, in which the principal caregivers of the subjects in the prevalence study were interviewed.
SETTING: Community and institutional settings in Canada, excluding those in the territories. PATIENTS: All patients with dementia 65 years and older as determined from the CSHA. Patients with dementia under 65 were also considered. OUTCOME MEASURES: Costs of paid and unpaid services in the community, care in long-term care institutions, drugs, hospitalization, diagnosis and research.
RESULTS: The total annual net cost of dementia was estimated to be over $3.9 billion. Costs associated with elderly patients in the community were estimated to be $1.25 billion ($615 million for paid services, $636 million for unpaid services), whereas costs for patients in long-term care institutions were $2.18 billion. Costs were about $74 million for drugs, hospitalization and diagnosis, $10 million for research and $389 million related to patients under age 65.
CONCLUSION: The annual net economic cost of dementia in Canada is at least $3.9 billion. The most significant component of the total cost was for care in long-term care institutions and for assistance with ADLs by professionals, family and friends in the community. The economic burden of dementia is significant not only for patients, their families and friends, but also for society.

Entities:  

Mesh:

Year:  1994        PMID: 7954140      PMCID: PMC1337410     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  5 in total

1.  The economic costs of Alzheimer's disease.

Authors:  J W Hay; R L Ernst
Journal:  Am J Public Health       Date:  1987-09       Impact factor: 9.308

2.  Health care costs of older persons with cognitive impairments.

Authors:  T A Coughlin; K Liu
Journal:  Gerontologist       Date:  1989-04

3.  The Modified Mini-Mental State (3MS) examination.

Authors:  E L Teng; H C Chui
Journal:  J Clin Psychiatry       Date:  1987-08       Impact factor: 4.384

4.  Evaluation of the costs of caring for the senile demented elderly: a pilot study.

Authors:  T W Hu; L F Huang; W S Cartwright
Journal:  Gerontologist       Date:  1986-04

5.  The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort.

Authors:  H G Welch; J S Walsh; E B Larson
Journal:  J Am Geriatr Soc       Date:  1992-03       Impact factor: 5.562

  5 in total
  28 in total

Review 1.  The epidemic of Alzheimer's disease. How can we manage the costs?

Authors:  N Johnson; T Davis; N Bosanquet
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

Review 2.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Autonomy, authenticity, or best interest: everyday decision-making and persons with dementia.

Authors:  S Holm
Journal:  Med Health Care Philos       Date:  2001

Review 4.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

5.  The general public's willingness to pay for tax increases to support unrestricted access to an Alzheimer's disease medication.

Authors:  Mark Oremus; Jean-Eric Tarride; Parminder Raina; Lehana Thabane; Gary Foster; Charlie H Goldsmith; Natasha Clayton
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

Review 6.  The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together.

Authors:  F J Molnar; W B Dalziel
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

Review 7.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  The independent contribution of executive functions to health related quality of life in older women.

Authors:  Jennifer C Davis; Carlo A Marra; Mehdi Najafzadeh; Teresa Liu-Ambrose
Journal:  BMC Geriatr       Date:  2010-04-01       Impact factor: 3.921

9.  Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.

Authors:  Ging-Yuek R Hsiung; A Dessa Sadovnick; Howard Feldman
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

Review 10.  The prevalence, cost implications, and management of sleep disorders: an overview.

Authors:  Jamil L Hossain; Colin M Shapiro
Journal:  Sleep Breath       Date:  2002-06       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.